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Original article
Hypertension affects 1 in 3 adults worldwide1 and contrib-
utes to 51% of deaths due to stroke and 45% of deaths due to 
coronary heart disease.2
Low adherence to antihypertensive medication is com-
mon and contributes to poor blood pressure (BP) control 
and adverse outcomes.3 In the United States, more than 36% 
of adults treated for hypertension have uncontrolled BP.4 
Low patient adherence to antihypertensive medication is 
the most significant, modifiable, patient-related barrier to 
achieving controlled BP.5
Since dissatisfaction with conventional antihypertensive 
treatment is common, use of complementary and alternative 
treatment for hypertension is increasing.6 Garlic preparations, 
as a possible form of complementary alternative medicine, are 
among the most popular forms of herbal supplements in the 
United States.7 The 2002 US National Health Interview Survey 
showed that 421 of 10,525 (4%) persons with cardiovascular 
disease in the United States used garlic preparations.8
Garlic is claimed to have a moderate BP–reducing 
effect.9 A recently published metaanalysis of 11 randomized 
controlled trials on the effect of garlic on BP concluded that 
garlic preparations are better than placebo in reducing BP.10 
However, only 4 of the 11 studies exclusively included indi-
viduals with hypertension and the metaanalysis did not sys-
tematically assess influence of trial quality on effect size.
In this metaanalysis, we included recently published tri-
als to evaluate the effect of garlic on BP in individuals with 
hypertension and systematically assessed risk of bias.
METHODS
Information sources and search
We searched the electronic databases PubMed, Embase, 
Cochrane Library, and Web of Science using the search terms 
“garlic” and “blood pressure” or “hypertension” from their 
inception through March 2014. Our search was then restricted 
to articles indexed as randomized clinical trials (for details of 
the search strategy in PubMed, see Supplementary material). 
There was no language restriction. We also searched trial 
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registries of ongoing trials and contacted authors of identi-
fied trials to obtain additional data where necessary.
Study selection
To be eligible, a trial had to be a randomized controlled 
trial that compared a garlic preparation with placebo or care 
as usual and included hypertensive patients with baseline 
BP of systolic blood pressure (SBP) ≥140 mm HG, diastolic 
blood pressure (DBP) ≥90 mm Hg, or both, irrespective of 
treatment status. Trials were required to report BP values 
at baseline and after a follow-up of at least 4 weeks. Two 
reviewers (A.N., A.R.) independently screened the retrieved 
database files and the full text of potentially eligible studies 
for relevance. Disagreement was resolved by consensus.
Data collection and risk-of-bias assessment
Two reviewers independently abstracted data concern-
ing baseline characteristics of included individuals; types 
and doses of garlic preparations used; presence or absence 
of antihypertensive treatment at baseline; potential co-
interventions; and the number and methods of BP measure-
ments, the patients’ position during BP measurements, and 
the specified outcomes (see below). We assessed risk of bias 
for each included study at the level of selected outcomes sug-
gested by the Cochrane Collaboration.11
Outcomes and data extraction
Two authors (A.N., A.R.) independently extracted pub-
lished trial data and additional data provided by the original 
investigators. Our primary endpoints were the values of SBP 
and DBP at baseline and at the end of follow-up. In addition, 
we were interested in any clinical outcome data or records of 
adverse events, if available.
Statistical analysis
We used a random effects model (Review Manager 5.2, 
Copenhagen, Denmark: The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2012) to measure weighted mean 
differences (WMDs) in SBP and DBP from baseline until the 
end of follow-up.
In case standard deviations (SDs) for changes from baseline 
values were not available in all but 3 trials,12–14 we calculated 
missing SDs by imputing values for a correlation coefficient 
of 0.5 in trials providing baseline and final SDs,15–17 and con-
ducted sensitivity analyses using the SD values calculated by 
imputing correlation coefficients of 0.7 and 1.0.18 When infor-
mation on SDs of changes of BP values between baseline and 
end of follow-up and for absolute BP values at the end of fol-
low-up were missing, we imputed the median by use of an SD 
from the remaining trials.19 We assessed potential publication 
bias by creating a funnel plot for the mean differences in SBP 
and DBP.20 Heterogeneity among combined study results was 
assessed using the Cochran Q test and by the degree of incon-
sistency (I2).21 In order to explore potential heterogeneity and 
to check the robustness of the results, we conducted several 
prespecified subgroup and sensitivity analyses.
RESULTS
Nine trials with 577 patients fulfilled our inclusion crite-
ria (Figure 1). In 1 additional trial, mean BP values of the 
42 participants were normal at the time of study recruit-
ment but slightly hypertensive after a run-in period and 
start of intervention.22 Since it remained unclear whether 
these individuals were truly hypertensive or not, this tri-
al’s results were only included in an additional sensitivity 
analysis.
Four trials included treatment-naive individuals.12,13,23,24 
One trial included both treatment-naive as well as insuf-
ficiently controlled individuals taking antihypertensive 
drugs,16 and 3 trials included treated hypertensive individu-
als with insufficiently controlled hypertension (≥140/90 mm 
Hg).14,15,17 One trial did not report whether included indi-
viduals were treatment naive or insufficiently controlled 
with antihypertensive drugs.25
In 2 of the 9 included trials,13,17 only a subgroup of 
included individuals had BP ≥140/90 mm Hg, leaving 482 
subjects to be included in the metaanalysis. We included 
all individuals in the Holzgartner trial16 since no separate 
BP values were reported for individuals with and without 
BP ≥140/90 mm Hg at baseline. Mean age of included indi-
viduals ranged from 50 to 70 years. One trial included men 
only.12
Six trials evaluated the effect of garlic preparations specifi-
cally in individuals with hypertension, 3 trials in individu-
als with dyslipidemia.16,24,25 Six trials had a follow-up of 12 
weeks, and the 3 other trials had follow-up periods of 8, 16, 
and 26 weeks, respectively.12,24,25
Characteristics of the included trials are summarized in 
Tables 1 and 2.
Figure  1. Trial flow. Abbreviations: BP, blood pressure; RCT, rand-
omized controlled trial.
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Types of garlic preparations used
All trials reported the dose of the garlic preparation used 
(Table  1). Six trials used only dried garlic powder (4 tri-
als using Kwai),15,16,23,25 and 1 trial used garlic powder of 
unknown origin that was described to be equivalent with 
Kwai.24 One trial12 compared 3 groups using garlic prepara-
tions (2 groups using 600 mg and 2,400 mg of time-released 
garlic powder (Allicor) daily, and 1 group used 900 mg of 
garlic powder (Kwai) daily) with a placebo group. For the 
purpose of this analysis, we pooled the data of all 3 garlic 
preparations and compared them with placebo. In another 
trial,13 crushed garlic was kneaded and pulverized together 
with egg yolk in a weight ratio of 80:20. This mixture was 
described as garlic homogenate (a traditional Japanese garlic 
preparation). Two trials by the same author used aged garlic 
extract (Kyolic).14,17 One of these trials was a dose-response 
trial that compared 3 doses of aged garlic extract (240 mg, 
480 mg, and 960 mg daily) with placebo. For the purpose 
of this analysis, we pooled the data of the groups receiving 
480 and 960 mg/day and compared them with the placebo 
group14 since there was no difference in BP between the 
groups receiving placebo or 240 mg aged garlic extract.
Types of BP measurement devices used for outcome 
assessment
All trials reported office BP measurements. Four trials did 
not describe which type of BP measurement device was used 
or whether a mean of repeated measurements or a single value 
was recorded.16,23–25 Two trials did not describe the device used 
but mentioned performance of repeated measurements.12,15 
One trial reported 2 BP measurements in the supine and 
standing position;15 another trial exclusively relied on a mean 
of 12 BP measurements (second and third BP measurement in 
both arms in standing, sitting, and supine positions).12
We used sitting BP measurements where available and 
supine BP measurements when only supine and standing BP 
measurements were reported. Three trials used automated 
sphygmomanometer and calculated the mean of repeated 
measurements in the sitting position.13,14,17
Risk-of-bias assessment
Results for the risk-of-bias assessments are presented 
in Table  3. The sequence generation for randomization 
was adequate in 5 trials12–14,16,17 and unclear in 4 tri-
als.15,23–25 Concealment of group allocation was unclear 
in 5 trials15,16,23–25 and adequate in 4 trials.12–14,17 Risk-of-
performance bias was considered to be low in all trials. 
Detection bias was considered to be low in 4 trials12–14,17 
and unclear in 5 trials.15,16,23–25 Four trials conducted an 
intention-to-treat-analysis.13,14,17,25 No trial explicitly 
reported industry funding; however, in 2 trials, at least 
1 study author could be identified as an employee of the 
company producing the garlic preparation under investi-
gation.13,24 Since study protocols were not available for all 
but 2 trials,14,17 we rated the risk of selective reporting bias 
Table 3. Risk-of-bias review of included studies
Study (First  
Author, Year)
Risk-of- 
selection 
bias: random 
sequence 
generation
Risk-of- 
selection bias: 
concealment of 
allocation
Risk-of- 
performance 
bias: blinding of 
patients and health 
care providers
Risk-of-detection 
bias: blinding 
of outcome 
assessment 
personnel
Risk-of- 
attrition bias: 
incomplete 
outcome 
data
Risk-of- 
reporting 
bias: selective 
reporting Risk of other biases
J. Kandziora,  
1988
Unclear Unclear Low Unclear Unclear Unclear Funding not 
mentioned
G. Vorberg,  
1990
Unclear Unclear Low Unclear Lowa Unclear Funding not 
mentioned
W. Auer, 1990 Unclear Unclear Low Unclear Unclear Unclear Funding not 
mentioned
H. Holzgartner, 
1992
Low Unclear Low Unclear Low Unclear Low
O.S. De Santos, 
1993
Unclear Unclear Low Unclear high Unclear Industry funding
I. Sobenin, 2009 Low Low Low Low Low Unclear Low
K. Ried, 2010 Low Low Low Low Lowa Low Low
Y. Nakasone,  
2013
Low Low Low Low Lowa Unclear Industry unding
K. Ried, 2013 Low Low Low Low Lowa Low Low
I. Sobenin,  
2008b
Low Low Low Low Unclear Unclear Low
Unclear, insufficient information about the process to permit judgment of low risk or high risk; industry funding, at least 1 author affiliated with 
company that produces garlic preparations.
aIntention-to-treat analysis.
bTrial only included in sensitivity analysis.
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Figure  2. Funnel plots for changes in systolic and diastolic BP. (A) Changes in systolic blood pressure. (B) Changes in diastolic blood pressure. 
Abbreviations: MD, mean difference; SE, standard error.
for these trials as unclear. The relatively small number of 
included trials precluded a sensitive exploration of publica-
tion bias (Figure 2).
Changes in SBP and DBP
SBP was more effectively reduced in individuals treated 
with garlic preparations than in individuals treated with 
placebo (WMD, −9.1 mm Hg; 95% CI, −12.7 to −5.4; P 
for heterogeneity  =  0.0006; I 2  =  71%). Similarly, DBP was 
more effectively reduced in individuals treated with gar-
lic preparations than in individuals treated with placebo 
(WMD, −3.8 mm Hg; 95% CI, −6.7 to −1; P for heterogene-
ity = 0.00001; I 2 = 80%) (Figure 3).
The observed heterogeneity for changes in SBP was 
reduced by restricting analyses to higher-quality tri-
als. Changes in SBP were less pronounced but still in 
favor of individuals allocated to garlic preparations when 
analyses were restricted to trials using intention-to-treat 
analysis,13,14,17,25 concealed treatment allocation, blinded 
outcome assessment, and automated BP measurement 
devices;13,14,17 to trials without necessity to impute SDs for 
changes in mean BP differences;12–14 to trials not explic-
itly mentioning industry support;12,14–17,23,25 and to trials 
using aged extract rather than other garlic preparations 
(Table 4).14,17
Various sensitivity analyses could not elucidate further rea-
sons for the high inconsistency of observed changes in DBP. 
Only when analysis was restricted to trials without imputed 
SDs for the mean difference in BP changes did heterogeneity 
disappeared (Table 4).
Sensitivity analyses using correlation coefficients of 0.7 and 
1.0 for SD values calculated by imputing or adding the trial 
where it was unclear whether included individuals were truly 
hypertensive or not22 did not result in substantial changes of 
BP differences or heterogeneity.
Adverse events
Seven of 9 trials reported on adverse events. No trial 
reported any serious adverse events. One trial reported 1 
death not considered to be related to the garlic treatment.24 
Two trials reported that there was no difference in adverse 
events between garlic preparations and placebo.13,23 In 1 trial 
that compared a garlic preparation with bezafibrate,16 11 of 47 
individuals randomized to garlic and 7 of 47 individuals ran-
domized to bezafibrate reported minor side effects (sensation 
of repletion, lack of appetite, headaches and vertigo, palpita-
tions, myalgia, tiredness). In 2 trials 24% and 23% of individu-
als taking garlic preparations experienced bloating, flatulence, 
and reflux compared with 8% and 2% of individuals in the 
placebo group.14,17
Only 3 trials reported dropouts in the garlic groups due to 
adverse events in 5 of 105 (5%) individuals; all events were 
related to gastrointestinal symptoms (bloating, discomfort/
mild pain).14,17,24
DISCUSSION
In this metaanalysis, we observed a statistically significant 
reduction in SBP and DBP in hypertensive individuals treated 
with garlic preparations; however, heterogeneity was high. 
When we restricted analyses to higher-quality trials, effects 
were less pronounced but remained significant, with low het-
erogeneity for SBP but not for DBP. The observed differences 
are clinically important, and side effects associated with garlic 
preparations were rare and mild.
Our study did have strengths. We carried out a comprehen-
sive literature search for randomized controlled trials com-
paring garlic preparations with placebo or care as usual in 
hypertensive individuals with a minimal follow-up of 4 weeks. 
The results of our metaanalysis remained robust across vari-
ous subgroup and sensitivity analyses, including differences in 
trial quality and types of garlic preparations used.
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Table 4. Comparison of subgroupse
Type of BP WMD (95% CI)
Test for 
heterogeneity Inconsistency WMD (95% CI)
Test for 
heterogeneity Inconsistency
ITT analysis (13, 14, 17, 25) No ITT analysis or unclear
SBP (mm Hg) -6.1 (–9.2 to –2.9) P = 0.54 I2 = 0% –11.2 (–17.3 to –5.2) P = 0.0001 I2 = 83%
DBP (mm Hg) –1.2 (–6.8 to 4.4) P = 0.001 I2 = 81% –5.2 (–8.9 to –1.5) P < 0.0001 I2 = 84%
Dried garlic preparations (12, 15, 16, 23–25)) Not dried garlic preparations
SBP (mm Hg) –10.6 (–15.4 to 
– 5.8)
P = 0.004 I2 = 78% –5 (–8.7 to –1.2) P = 0.58 I2 = 0%
DBP (mm Hg) –5.4 (–8.4 to –2.4) P = 0.00001 I2 = 80% 1.5 (–6.9 to 9.8) P = 0.01 I2 = 78%
Aged garlic (14, 17) Not aged garlic extract
SBP (mm Hg) –7.5(–13.5 to 
–1.4)
P = 0.86 I2 = 0% –9.5 (–13.8 to –5.2) P = 0.0001 I2 = 78%
DBP (mm Hg) 4.8 (–5.5 to 15) P = 0.12 I2 = 59% –5.1 (–7.7 to –2.5) P = 0.00002 I2 = 78%
Industry funded (13, 24) Not industry funded or unclear
SBP (mm Hg) –13.6 (–33.7 to 
6.6)
P < 0.00001 I2 = 96% –7.7 (–9.6 to –5.9) P = 0.8 I2 = 0%
DBP (mm Hg) –6.5 (–13.3 to 0.4) P = 0.005 I2 = 87% –2.9 (–6.3 to 0.4) P < 0.00001 I2 = 80%
SBP >160 mm Hg (15, 23) SBP <160 mm Hg
SBP (mm Hg) –10.9 (–15.4 to 
–6.3)
P = 0.88 I2 = 0% –8.7 (–13.1 to –4.3) P = 0.0002 I2 = 77%
DBP (mm Hg) –7 (–9.8 to –4.2) P = 0.26 I2 = 21% –2.6 (–6.1 to 0.9) P < 0.00001 I2 = 82%
Adequate concealment, blinded outcome assessment, 
and automated BP measurement (13, 14, 17)
No adequate concealment, blinded outcome 
assessment, or automated BP measurement
SBP (mm Hg) –5 (–8.7 to –1.2) P = 0.58 I2 = 0% –10.6 (–15.4 to –5.8) P = 0.0004 I2 = 78%
DBP (mm Hg) 1.5 (–6.9 to 9.8) P = 0.01 I2 = 78% –5.4 (–8.4 to –2.4) P = 0.0001 I2 = 80%
SBP (mm Hg) DBP 
(mm Hg)
No SD for BP difference imputed (14, 15, 17) SD for BP difference imputed
–6.3(–8.5 to 4.1) P = 0.41 I2 = 0% –2 (–3.9 to –0.03) P = 0.74 I2 = 0%
–11(–16.3 to 5.7) P = 0.002 I2 = 74% –4.5(–8.4 to 0.6) P = 0.00001 I2 = 84%
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; ITT, intention to treat; SBP, systolic blood pressure SD, standard deviation; 
WMD, weighted mean difference.
Our analysis did have several limitations. The overall esti-
mates for both SBP and DBP were highly heterogeneous with 
relatively large effect sizes and large CIs. All included trials 
were of small sample size. Empirical evidence suggests that 
effect sizes from small trials tend to be larger than those 
of highly powered trials.19 In addition, we were forced to 
impute SDs for the changes in BP for 6 of 9 trials.
The overall quality of the majority of included trials was 
moderate. Only a few trials conducted an intention-to-
treat analysis, used adequate methods for concealed treat-
ment allocation, and standardized BP measurements with 
automated sphygmomanometers. Summary estimates from 
trials that used more adequate methods were considerably 
lower, which is of concern. In addition, we were unable to 
explain the observed inconsistency for the results of changes 
in DBP despite various sensitivity analyses performed. Only 
when analysis was restricted to trials without imputed SDs 
for the mean difference in BP changes did heterogeneity 
disappear.
Dosages and type of garlic preparations used in included 
trials were heterogeneous. Most trials used garlic powder 
dosages of 600–2,400 mg/day, providing 3.6–13.6 mg of 
allicin. In comparison, fresh garlic cloves (approximately 
2 g) each yield 5–9 mg of allicin.26 It must be noted that dif-
ferent garlic preparations have variable effectiveness on BP. 
For example, ingestion of heat-treated garlic may yield only 
minimal allicin compounds.27,28 Thus, the different garlic 
preparation methods used in the trials may have contributed 
to the heterogeneous study findings and preclude an appro-
priate analysis of a dose relationship. Finally, the duration of 
intervention in all trials was relatively short, with a mean of 
13.5 weeks. It has yet to be determined whether the observed 
differences in BP in these short intervention trials last in the 
long term due to potential regression dilution bias.29
Information about how garlic could influence BP origi-
nates primarily from animal or in vitro models; however, 
the exact mechanism remains to be elucidated. Possible 
mechanisms are inhibition of the angiotensin-converting 
enzyme,30 an increase in the concentration and activity of an 
array of vasodilatory agents including nitrous oxide (NO),31 
and stimulation of erythrocytes to produce hydrogen sulfide, 
which acts as a signaling molecule by opening K-ATP chan-
nels in smooth muscle cells and thus inducing depolarization 
and blood vessel dilatation.32 In particular, S-allylcysteine 
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seems to increase NO production within endothelial cells 
and thus enhances the elasticity of blood vessels.28
Previous metaanalyses in which the effect of gar-
lic preparations on BP was evaluated all included both 
individuals with and without hypertension. Also, they 
included fewer individuals with hypertension and none 
of them systematically assessed the effect of trial qual-
ity on interpretation of findings. The metaanalysis by 
Silagy et  al.33 included 415 normo- and hypertensive 
individuals from 7 randomized controlled trials, with 
only 3 trials including hypertensive individuals, the 
metaanalysis by Reinhart et  al.,34 which included 410 
individuals from 10 randomized controlled trials with 
only 3 trials including individuals with elevated SBP 
(n  =  139), and the metaanalysis by Ried et  al.,10 which 
included 11 randomized controlled trials with only 4 tri-
als including hypertensive individuals (n  =  231). In all 
of these metaanalyses, SBP and DBP were lowered more 
efficiently in individuals treated with garlic in the hyper-
tensive population. Thus, the beneficial effect of garlic 
preparations on BP control in hypertensive individuals 
observed in previous subgroup metaanalyses is substan-
tiated by our metaanalysis.
Based on short-term evidence, the BP-lowering effect of 
garlic preparations seems comparable to the effect of the 5 
main classes of BP-lowering drugs (diuretics, beta block-
ers, calcium channel blockers, angiotensin-converting 
enzyme inhibitors, and angiotensin II receptor blockers). 
In a metaanalysis of 354 short-term randomized placebo-
controlled trials of these 5 BP-lowering drugs in fixed dose, 
the 5 main classes of BP-lowering drugs produced similar 
reductions in BP, with a standard dose of a drug on average 
lowering SBP by 9.1 mm Hg and DBP by 5.5 mm Hg, which 
is similar to the BP-lowering effects of garlic preparations 
observed in this study.35
Although no serious side effects have been reported for 
garlic preparations, garlic odor is the most common36 and 
may limit the acceptability of some garlic preparations.
Implications for further research and clinical practice
More research is required to understand the mechanisms 
for the BP-lowering effect of garlic preparations. Current 
evidence on the effectiveness of garlic preparations in lower-
ing BP is in hypertensive individuals and is primarily based 
on short-term evidence from small randomized controlled 
Figure 3. Mean changes in systolic and diastolic blood pressure. (A) Mean changes in systolic blood pressure. (B) Mean changes in diastolic blood pres-
sure. Abbreviations: CI, confidence interval; df, degrees of freedom; I2 = inconsistency; SD, standard deviation.
422 American Journal of Hypertension 28(3) March 2015
Rohner et al.
trials. Many of these trials suffer from methodological short-
comings. More than 25  years after publication of the first 
randomized controlled trial that compared a garlic prepa-
ration with a placebo for the treatment of hypertension,15 
we still do not know whether garlic preparations lower BP 
in the long term. There is an urgent need for an adequately 
powered randomized controlled trial using standardized BP 
measurements with automated sphygmomanometers for 
blinded outcome assessment of BP response in hypertensive 
individuals treated with garlic preparations.
CONCLUSIONS
Garlic preparations look promising as an herbal medication 
for reducing high BP. However, considering current trials to 
be short term, a well-conducted, sufficiently powered long-
term trial is needed to assess the BP-lowering capacities of a 
standardized form of a garlic preparation. As of now, there is 
insufficient evidence to have confidence that garlic prepara-
tions are an effective alternative or complementary/adjunct 
herbal medication to conventional antihypertensive drugs.
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